Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Key facts

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Principal Investigator

Giovanni Martinelli

Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Italy

Intervention

Inotuzumab Ozogamicin (IO)(drug)

Enrollment

76 enrolled

Eligibility

18 years · All sexes

Timeline

2019 – 2022

Study locations (30)

• Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona- Sod Clinica Ematologica, Ancona, Italy
• Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia, Ascoli Piceno, Italy
• Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia, Bergamo, Italy
• Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia, Bologna, Italy
• As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo, Bolzano, Italy
• Asst Degli Spedali Civili Di Brescia - Uo Ematologia, Brescia, Italy
• Aso S. Croce E Carle - Cuneo - Sc Ematologia, Cuneo, Italy
• Irccs Aou San Martino - Genova - Uo Clinica Ematologica, Genova, Italy
• Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia, Lecce, Italy
• I.R.S.T. Srl Irccs - Meldola - Sc Oncologia Medica, Meldola, Italy
• Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia, Mestre, Italy
• Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia, Milan, Italy
• Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia, Milan, Italy
• Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di Oncoematologia, Milan, Italy
• Ao Di Rilievo Nazionale Antonio Cardarelli - Napoli - Uoc Ematologia Con Trapianto Di Midollo, Naples, Italy
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06326008
  Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06859424
  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE2, PHASE3NCT06860269
  A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06895538
  Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
  Peking University First Hospital
• RECRUITINGNANCT06960993
  Mosaic Trial for Stem Cell Transplant Recipients
  Northwestern University
• RECRUITINGPHASE2NCT06816134
  Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06608732
  Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
  Institute of Hematology & Blood Diseases Hospital, China
• ACTIVE NOT RECRUITINGNANCT05968963
  Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
  University of Miami

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →